Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Synuca Therapeutics ApS
APS
Active
CVR 45367282
Ole Maaløes Vej 3, 2200
København N
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2025 · 1 year old
2 employees
Monitor
Share
Denmark
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Synuca Therapeutics ApS
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Gross profit
DKK millions
0M
0M
0M
-1M
-1M
0M
2025
EBITDA
DKK millions
0M
0M
0M
-1M
-1M
0M
2025
Income statement
DKK thousands
Item
2025
Gross profit
-256
Staff expenses
-69
EBITDA
-325
Depreciation & amort.
-0
EBIT
-325
Net financials
-21
Profit before tax
-346
Tax
-74
Net profit
-273
Balance sheet
DKK thousands
Item
2025
Total assets
345
Equity
-267
Long-term debt
558
Short-term debt
54
Total debt
612
Financial ratios
5-year trend
EBITDA margin (of gross profit)
-32494400.0%
This company
2025
2025
Equity ratio
-77.6%
This company
38.2%
Market median
303% below market
2025
2025
Return on equity
-27281800.0%
This company
18.4%
Market median
148270752% below market
2025
2025
Net profit margin (of gross profit)
-27281800.0%
This company
2025
2025
Asset turnover (of gross profit)
-0.74×
This company
2025
2025
Debt / equity
2.29×
This company
0.62×
Market median
269% above market
2025
2025
Annual reports & filings
Annual report 2025
Filed via CVR / Virk · Period 2025-01-30 – 2025-12-31
View
PDF
More on Synuca Therapeutics ApS
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
